Elicio Therapeutics Showcases Groundbreaking Cancer Research Efforts
Elicio Therapeutics Unveils Future Presentations on Cancer Vaccines
Elicio Therapeutics, Inc. (NASDAQ: ELTX), a pioneering biotechnology company, has announced significant upcoming presentations that focus on their innovative mKRAS-specific amphiphile vaccines. These presentations are set to take place in the upcoming months, showcasing the latest advancements in their clinical trials and research efforts.
First Presentation at AACR Special Conference
The initial presentation is scheduled at the American Association for Cancer Research (AACR) Special Conference, which will occur from September 15-18, focusing on advancements in pancreatic cancer research. Esteemed Dr. Eileen O’Reilly from Memorial Sloan Kettering Cancer Center will share insights from the recent Phase I AMPLIFY-7P trial.
Details of the AACR Presentation
Title: Pancreas Cancer 2024: Translating genomic findings into clinical actionability
Presenter: Dr. Eileen M. O’Reilly
Date and Time: September 15, 5:50 p.m. ET
Second Presentation at RAS-Targeted Drug Development Summit
Following this, the second presentation will take place on September 25 at the RAS-Targeted Drug Development Summit. Dr. Pete DeMuth, Chief Scientific Officer at Elicio, will present critical information on the clinical translation of Elicio’s RAS-targeted amphiphile vaccines, focusing on their mKRAS vaccination strategy.
Details of the RAS Summit Presentation
Title: Targeting mKRAS Vaccination to the Lymph Nodes to Promote Anti-tumor Immunity
Presenter: Dr. Peter C. DeMuth
Date and Time: September 25, 11:45 a.m. ET
Third Presentation at Precision Oncology Institute Symposium
The third presentation occurs on October 1 at the Stuart and Molly Sloan Precision Oncology Institute Symposium, where Dr. Christopher Haqq, Executive Vice President and Chief Medical Officer of Elicio, will discuss the Phase I experience with two specific vaccine candidates, ELI-002 2P and ELI-002 7P.
Details of the Precision Oncology Institute Presentation
Title: Amplifying tumor specific immunity through lymph node targeted mKRAS-specific amphiphile vaccine in gastrointestinal tumors
Presenter: Dr. Christopher M. Haqq
Date and Time: October 1, 9:40 a.m. PT
CEO's Insight on Recent Patient Data
Robert Connelly, Elicio’s CEO, expressed his enthusiasm regarding the recent data from patients who received the 7-peptide version of ELI-002. He highlighted that T cell response data corresponded positively with reduced tumor biomarker levels and a lower risk of progression or death. Connelly remarked, "With $43 million raised in funding for 2024, we're optimistic about our potential clinical updates and upcoming results from the AMPLIFY-201 trial. We anticipate sharing further insights in the latter part of this year and an interim analysis from the AMPLIFY-7P randomized Phase 2 trial early next year."
Understanding Elicio Therapeutics
Elicio Therapeutics is addressing some of the most aggressive cancer types through their advanced pipeline of lymph node-targeted immunotherapies. Utilizing their innovative AMP technology, they aim to channel therapeutic payloads directly to lymph nodes, thus enhancing the immune system's natural ability to combat cancer. This approach is designed to educate, activate, and amplify the activity of cancer-specific T cells, vital for recognizing and eliminating tumors effectively.
About the Amphiphile Platform
The company's proprietary Amphiphile (AMP) platform appears to offer promising results by delivering investigational therapeutics specifically to lymph nodes. This targeted delivery intends to significantly improve the immune response’s magnitude and durability, potentially translating into better clinical outcomes compared to traditional methods. Elicio's technology, developed at the Massachusetts Institute of Technology, shows significant promise across various cancer types.
Frequently Asked Questions
What is Elicio Therapeutics known for?
Elicio Therapeutics focuses on developing innovative immunotherapies for aggressive cancers, particularly through their unique amphiphile vaccines.
When will these upcoming presentations occur?
The presentations are scheduled for September 15, September 25, and October 1 in 2024.
Who are the presenters at these conferences?
Dr. Eileen O’Reilly, Dr. Pete DeMuth, and Dr. Christopher Haqq will present at the respective conferences.
What technology does Elicio use in its research?
Elicio utilizes its Amphiphile platform, which allows for targeted delivery of cancer vaccines to the lymph nodes, enhancing the immune response.
How is patient data relevant to Elicio’s research?
Patient data helps Elicio understand the effectiveness of their vaccines, as seen with positive correlations between T cell responses and tumor biomarker reductions.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- C4 Therapeutics Reveals Promising CFT1946 Trial Results
- Prelude Therapeutics Reveals Early Successes with PRT3789 Trial
- West Cancer Center Pioneers Holographic Patient Consultations
- Charging Robotics Showcases Innovative EV Solutions in Dubai
- RenovaroCube Showcases Innovative Cancer Diagnostics Research
- Outlook Therapeutics Drives Innovation in Eye Disease Treatment
- Verve Therapeutics, Inc. Investors Invited to Join Class Action
- Securities Fraud Allegations Against Sage Therapeutics Explored
- Effective Treatment of Nonmelanoma Skin Cancer with IGSRT
- TOPBAND Showcases Innovations at Premier Energy Exhibition
Recent Articles
- Revolutionizing Customer Engagement: Rezolve AI Partners Up
- CorMedix Inc. Updates on Participation at Healthcare Conference
- Jyske Realkredit Announces Launch of New Fixed Rate Bonds
- ParaZero Technologies Expands Defense Solutions with C-UAS Order
- Understanding Alliance Trust PLC's Latest Net Asset Value Insights
- Insights on Rathbones Group Plc in Property Market
- Jyske Realkredit Launches New Covered Bonds in Copenhagen
- Exploring the Future of Commercial Payment Cards Through 2027
- Similarweb Ltd. Launches Major Share Offering to Boost Growth
- Emerging Trends in South Africa's Embedded Finance Landscape
- Exploring the Growth of Embedded Finance in Switzerland
- Cherry Hill Mortgage Investment Corporation Announces Q3 Dividends
- John Legend's Inspiring Performance Unites Fans and Philanthropy
- Jorge Perez's Remarkable Achievement in Technology Recognition
- Celebrating Jorge Perez: A Leading Voice in Tech Diversity
- Urban Poling Empowers Balance Awareness Alongside VeDA
- Discover the Future of Mobile Top-Up with Crypto Integration
- Exciting CJ Donaldson Autograph Event at Huntington Mall
- Transforming Small-Cap Markets: Insights from Dream Exchange
- Metify and SecEdge Join Forces for Enhanced Security Solutions
- Unveiling Political Divides in 'It Isn't Just Politics'
- Craft Holsters Launches In-Depth SIG Sauer Reviews for Fans
- Tineco Celebrates Amazon Recognition with Exclusive Discounts
- Enhancing Caregiver Experience: Combatting Wound Odors Effectively
- Market Movements: Boeing Struggles While RH's Sales Impress
- Wells Fargo Faces New Challenges in Asset Cap Removal Timeline
- Adobe Faces Challenges Amid Rising AI Competition and Forecasts
- Biden Administration's Import Regulations Impact E-Commerce Stocks
- United Airlines Partners with Starlink for Enhanced Wi-Fi Services
- Dyor App Unveils Innovative Token Collection for Investors
- Microstrategy Expands Bitcoin Holdings with $1.11 Billion Purchase
- Bybit's $DOGS Token Airdrop Sets New Standards in Crypto Market
- Gold Surges as US Dollar Faces Pressure from Fed Decisions
- US Economic Growth Forecast for Q3 Highlights Resilience
- Exploring High-Yield Investment Opportunities in REITs
- PDD Holdings Faces Challenges Amidst Rising Competition
- Exploring Retirement at 70: Key Considerations and Insights
- Gorilla Technology Unveils Strategic $6 Million Stock Repurchase Plan
- Gaxos.ai to Skyrocket Connections at Unite 2024 Conference
- Progressive Reports Strong August 2024 Financial Performance
- OFS Credit Company Reports Robust Q3 Results and Updates
- Future Growth Prospects of BitFuFu Inc. as a Mining Leader
- Diddy Places $61.5 Million Beverly Hills Mansion for Sale
- Ladder Capital Corp Declares Q3 2024 Dividend for Shareholders
- CureMint Welcomes Sales Leader John Klavon to Enhance Growth
- Innovative Housing Solutions: A Look at Canada's Progress
- WEBTOON Entertainment Inc. Investors Invited to Join Class Action
- Japan's Approval of KOSTAIVE® Vaccine Marks COVID-19 Milestone
- Nigerian Communities Demand Billions in Damages from Shell
- Progressive Corporation's August 2024 Financial Highlights